As part of our mission to eliminate cancer, Torrance Memorial Hunt Cancer Institute physicians conduct several clinical trials to test new treatments for both common and rare cancers. Look through our clinical trials list to find studies for which you may be eligible.

Hunt Cancer Institute Active Clinical Trials

These studies are currently enrolling participants.

Disease Title Summary Status Investigator
Breast Cancer RAVEL RB-AG-PLT-01 "EMBRACE" Evaluation of Novel Blood-Based Biomarkers for Detection of Breast Cancer (EMBRACE) Open/Active Swati Sikaria, MD
GI- COLORECTAL CANCER (CRC) NATERA "BESPOKE" 20-041-NCP BESPOKE Study of ctDNA Guided Therapy in Colorectal Cancer Open/Active Syed Jilani, MD
SOLID TUMOR: BREAST, STAGE 1 COLON, ALL LIVER CANCER LAM "ELITE" 001-2018 Collection of Blood from Healthy Patients, Patients with Benign Disease and Patients with Cancer Open/Active David Chan, MD

Active Trials - UCLA Trials

The following clinical trials are available at Torrance Memorial Physician Network Cancer Care and are in coordination with the TRIO-US / Clinical Trials Network.

Disease Title Summary Status Investigator
BREAST TRIO 033 ‐ Novartis CLEE011O12301C "NATALEE" Phase III, multicenter, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive, HER2-negative, early breast cancer (New Adjuvant TriAl with Ribociclib [LEE011]:NATALEE) Open/Active David Chan, MD
BREAST NSABP B-59 / GBG 96-GeparDouze TNBC A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negative Breast Cancer Followed by Adjuvant Continuation of Atezolizumab or Placebo. Open/Active David Chan, MD
BREAST Seattle Genetics SGNTUC-016 "HER2 CLIMB-02" Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with adotrastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer. Open/Active David Chan, MD
BREAST TRIO-038 - Roche WO42133 A RANDOMIZED, MULTICENTER, OPEN-LABEL, TWO-ARM, PHASE II, NEOADJUVANT STUDY EVALUATING THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF GDC-9545 PLUS PALBOCICLIB COMPARED WITH POSTMENOPAUSAL WOMEN. ANASTROZOLE PLUS PALBOCICLIB FOR POSTMENOPAUSAL WOMEN WITH ESTROGEN RECEPTOR-POSITIVE AND HER2-NEGATIVE UNTREATED EARLY BREAST CANCER Open/Active David Chan, MD
BREAST TRIO-US B-12 (TALENT) A Phase II, Multicenter, Open-Label Trial to Evaluate the Safety and Efficacy of trastuzumab deruxtecan (DS-8201a) with or without anastrozole for HER2 Low Hormone Receptor Positive (HR+) Breast Cancer in the Neoadjuvant Setting Open/Active David Chan, MD
PANCREATIC Ipsen "NAPOLI-3" An open-label, randomised, multicentre, phase III study of irinotecan liposome injection, oxaliplatin, 5-fluorouracil / leucovorin versus nab-paclitaxel plus gemcitabine in subjects who have not previously received chemotherapy for metastatic adenocarcinoma of the pancreas. Open/Active Hugo Hool, MD
LUNG - NON SMALL CELL LUNG CANCER Mirati 516-005 "SAPPHIRE" A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy. Open/Active Thomas Lowe, MD
CHRONIC LYMPHOCYTIC LEUKEMIA Acerta ACE-CL-311 (D8221C00001) CLL A Randomized, Multicenter, Open-Label, Phase 3 Study to Compare the Efficacy and Safety of Acalabrutinib (ACP-196) in Combination with Venetoclax with and without Obinutuzumab Compared to Investigator's Choice of Chemoimmunotherapy in Subjects with Previously Untreated Chronic Lymphocytic Leukemia Without del(17p) or TP53 Mutation. Open/Active Swati Sikaria, MD

Cedars-Sinai Trials

Disease Title Summary Status Investigator
BRAIN- GLIOBLASTOMA (GBM) NCI NRG-BN007 A RANDOMIZED PHASE II/III OPEN-LABEL STUDY OF IPILIMUMAB AND NIVOLUMAB VERSUS TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MGMT (TUMOR O-6-METHYLGUANINE DNA METHYLTRANSFERASE) UNMETHYLATED GLIOBLASTOMA Open/Active Andrew Horodner, MD & Jeremy Rudnick, MD
BRAIN METASTASES NCI ALLIANCE A071701 GENOMICALLY-GUIDED TREATMENT TRIAL IN BRAIN METASTASES Open/Active Andrew Horodner, MD & Jeremy Rudnick, MD
BREAST-DCIS AFT-25 "COMET" COMPARISON OF OPERATIVE TO MONITORING AND ENDOCRINE THERAPY (COMET) TRIAL FOR LOW RISK DCIS: A PHASE III PROSPECTIVE RANDOMIZED TRIAL, https://dcisoptions.org/ Open/Active Swati Sikaria, MD
BREAST NCI ALLIANCE A011401 "BWEL" RANDOMIZED PHASE III TRIAL EVALUATING THE ROLE OF WEIGHT LOSS IN ADJUVANT TREATMENT OF OVERWEIGHT AND OBESE WOMEN WITH EARLY BREAST CANCER Open/Active Swati Sikaria, MD & Arash Asher, MD
BREAST IIT2018-04-MCARTHUR-NEOHIP "NeoHIP" Neoadjuvant HER2-targeted Therapy and Immunotherapy with Pembrolizumab (neoHIP) Open/Active Swati Sikaria, MD & Heather McArthur, MD
BREAST NCI ALLIANCE A221505 "RT CHARM" RT CHARM: PHASE III RANDOMIZED TRIAL OF HYPOFRACTIONATED POST MASTECTOMY RADIATION WITH BREAST RECONSTRUCTION Open/Active Swati Sikaria, MD & Michelle Burnison, MD
GI- COLORECTAL CANCER (CRC) NCI ALLIANCE A021703 "SOLARIS" RANDOMIZED DOUBLE-BLIND PHASE III TRIAL OF VITAMIN D3 SUPPLEMENTATION IN PATIENTS WITH PREVIOUSLY UNTREATED METASTATIC COLORECTAL CANCER (SOLARIS) Open/Active Syed Jilani, MD & Jun Gong, MD
HEAD/NECK IIT2019-20-ZUMSTEG-HPVOPC Phase II Trial of De-Intensified Post-operative Chemoradiation Following Robotic Surgery for HPV-positive Oropharyngeal Cancer Open/Active Vanessa Dickey, MD & Zachary Zumsteg, MD
LUNG- NON SMALL CELL LUNG CANCER NCI SWOG LUNGMAP LUNGMAP: A MASTER PROTOCOL TO EVALUATE BIOMARKER-DRIVEN THERAPIES AND IMMUNOTHERAPIES IN PREVIOUSLY-TREATED NON-SMALL CELL LUNG CANCER (Lung-MAP Screening Study) Open/Active Andrew Horodner, MD & Karen Reckamp, MD
SOLID TUMOR "TAPUR" BY ASCO The Targeted Agent and Profiling Utilization Registry (TAPUR) Study, WWW.TAPUR.COM Open/Active Swati Sikaria, MD & Omid Hamid, MD

For More Information

For more information about the clinical trials at Torrance Memorial, call 310-517-7077.